NBI

NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy System

Retrieved on: 
Mercredi, mars 27, 2024
Cloud, Internet, QKD, Google Images, Safety, ICT, Software, Nippon Telegraph and Telephone, PQC, Computer, Collection, Communication, NTT, NBI, Cloud computing, Observation, Environment, Human, Physician, Endoscopy, Olympus Corporation, Digital twin, GPU, Graphics processing unit, APN, Post-quantum cryptography, Knowledge, Computer data storage

Cloud endoscopy system using NTT's high-speed, low-latency IOWN APN technology

Key Points: 
  • Cloud endoscopy system using NTT's high-speed, low-latency IOWN APN technology
    TOKYO, Mar 27, 2024 - (JCN Newswire) - NTT Corporation (NTT) and Olympus Corporation (Olympus) today announce that the two companies have jointly begun a demonstration experiment of a cloud endoscopy system that enables image processing on the cloud.
  • To realize a cloud endoscopy system, NTT and Olympus have started demonstration experiments centered on IOWN APN to solve technical problems in the network.
  • Based on the knowledge gained from the demonstration experiment, NTT and Olympus will jointly consider the commercialization of the cloud endoscopy system.
  • In this demonstration experiment, Olympus will provide the specific requirements and evaluation items for the cloud endoscopy concept, as well as the endoscopic equipment for the demonstration experiment.

EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates

Retrieved on: 
Vendredi, mai 3, 2024
USD, Annual, Alnylam Pharmaceuticals, TTR, Federal Reserve, Agios, BB Biotech, Mitapivat, NAV, Esperies, Accounting, Federal, Cardiomyopathy, NBI, Public expenditure, Prostate cancer, Obesity, Environment, DSM-IV codes, ADC, CRISPR, Patient, Thalassemia, Biotechnology, CRISPR Therapeutics, Initial public offering, Beam Therapeutics, Inflation, CHF, IRA, Drug development, Clinical trial, Significance, Therapy, Pharmaceutical industry

BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates

Key Points: 
  • BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
    The issuer is solely responsible for the content of this announcement.
  • Media release as at April 26, 2024
    Portfolio of BB Biotech AG as at March 31, 2024
    BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
    Investor sentiment in the biotech space continues to be shaped by the general interest rate environment.
  • Net profit for the first quarter of 2024 amounted to CHF 260 mn (net loss of CHF 254 mn in prior-year quarter).
  • While activity in the secondary market has already picked up, there have been few biotech IPOs so far this year.

Recurrence Data for Narrow Band Imaging™ (NBI™) Technology Show Value in the Fight Against Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Mercredi, avril 24, 2024
MIBC, Physician, University, Cancer, Urology, Eastern Virginia Medical School, Meta-analysis, Cystoscopy, Google Images, Risk, American Urological Association, Recurrence, American Cancer Society, NBI, AIST, Patient, Classification, Eye, Systematic, NMIBC, AUA, Diagnosis, Narrow-band imaging, Neoplasm, Associate, Bladder cancer, Vesica, Medical imaging

CENTER VALLEY, Pa., April 24, 2024 /PRNewswire/ -- Olympus, a global medical technology company committed to making people's lives healthier, safer, and more fulfilling, announced today data showing that the use of Narrow Band Imaging (NBI) technology with patients with non-muscle invasive bladder cancer (NMIBC) led to 37% less likelihood of recurrence over 12-35 months.1 

Key Points: 
  • As reported by the American Cancer Society, bladder cancer has one of the highest recurrence rates.2 Additionally, "recurrence and progression to muscle-invasive bladder cancer (MIBC) is highly variable, depending on tumor classification and grade at diagnosis.
  • For example, in patients diagnosed with low-grade noninvasive urothelial carcinoma (Ta), recurrence rates range from 30% to 60% at 5 years; however, the risk of progression to MIBC is ≤5%.
  • In contrast, patients with high-grade urothelial carcinoma invading into the lamina propria (T1) have progression rates of 30% to 70%."
  • NBI technology will also be available for demo at the Olympus booth at the American Urological Association (AUA) conference, May 3-6, 2024, in San Antonio, TX.

David McCourt and Vint Cerf speak on the 50th anniversary of the Internet on its past, present and future in an AI world

Retrieved on: 
Mercredi, avril 10, 2024
Education, McCourt, Internet, National broadband plan, Policy, School, Health, Economist, Artificial intelligence, Human, NBI, Public policy, Environment, Club, Farm, Record, Work, Father, Music, Government, Internet service provider

DUBLIN, April 10, 2024 /PRNewswire/ -- "It's a country's responsibility to ensure all citizens have high-speed broadband and access to the health and wealth that AI can bring to its people." This was the stark warning from Granahan McCourt founder and CEO David McCourt as he spoke at Costa Rica's prestigious Club de Investigación Tecnológica this week, urging all small countries like Costa Rica to take a leadership role in the global AI race.

Key Points: 
  • "We need guard rails, transparency, and fairness, but stopping the role of AI in the development of society is a mistake," continued McCourt.
  • Speaking alongside Vint Cert, recognized as one of "the fathers of the Internet", McCourt presented his vision for the future, adding: "Technology is a solution for cheaper and better education, cheaper healthcare, and a cleaner environment.
  • We've also spent time with amazing talents like Pedro Capmany, who has inspired the world with his use of AI in popular music.
  • We plan to tell these captivating stories, shot in Costa Rica's beautiful environments, and share them with the world."

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Mardi, mars 19, 2024
Research, Moyamoya disease, Quarter, Cardiovascular disease, Spirited, Growth, Exercise, Entrepreneurship, IL-6, Inflammation, Patient, SVP, Business development, Commercial, NASDAQ Biotechnology Index, MD, IND, Investment, Clinical trial, NBI, Investigational New Drug, Therapy, TRML, Medical research, Graves' ophthalmopathy, FDA, Food, Pharmaceutical industry

In October 2023, Tourmaline become a publicly-traded company via reverse merger with Talaris Therapeutics, including a concurrent private placement of $75.0 million.

Key Points: 
  • In October 2023, Tourmaline become a publicly-traded company via reverse merger with Talaris Therapeutics, including a concurrent private placement of $75.0 million.
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash, cash equivalents and investments were $203.0 million as of December 31, 2023, as compared to $8.3 million as of December 31, 2022.
  • Research and development expenses were $8.0 million for the fourth quarter of 2023, as compared to $3.8 million for the fourth quarter of 2022.
  • General and administrative expenses were $6.9 million for the fourth quarter of 2023, as compared to $1.1 million for the fourth quarter of 2022.

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Mercredi, mars 20, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Research, Multiple myeloma, Lung cancer, Partner, NMPA, Growth, NSCLC, CIDP, Partnership, Telephone, GSK, Patient, TED, NASDAQ Biotechnology Index, Epitope, Artificial intelligence, Sale, Myasthenia gravis, Neonatal Fc receptor, Fluorouracil, Graves' ophthalmopathy, Investment, Teclistamab, NBI, National Medical Products Administration, Johnson & Johnson, Drug development, Safety, Chicken, Machine learning, Gastrointestinal cancer, Immunoglobulin G, BLA, Chronic inflammatory demyelinating polyneuropathy, Pharmaceutical industry

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.
  • OmniAb launched two new technologies during 2023 including OmniDeep™ and, during the fourth quarter, OmnidAb™.
  • Fourth quarter 2023 and recent partner highlights include the following:
    Immunovant reported positive initial results for batoclimab in Graves’ disease (GD).
  • OmniAb was added to the Nasdaq Biotechnology Index (NBI) in the fourth quarter.

Quantum Experts Join Forces to Revolutionize European Quantum Computing

Retrieved on: 
Jeudi, mars 14, 2024
Science, Software, Nanotechnology, Research, Hardware, Data Management, Technology, Semiconductor, Noise, Partnership, Acquisition, NBI, Niels Bohr Institute, Machine learning, Multimedia, SME, Microscope

This landmark initiative brings together quantum experts from the United Kingdom, Germany, and Denmark with a shared goal of accelerating the development and commercialization of photonic quantum computing technologies to deliver quantum advantage.

Key Points: 
  • This landmark initiative brings together quantum experts from the United Kingdom, Germany, and Denmark with a shared goal of accelerating the development and commercialization of photonic quantum computing technologies to deliver quantum advantage.
  • It will draw upon single-photon sources from Sparrow Quantum and NBI, single-photon detectors from Pixel Photonics, and full-stack photonic quantum computing system architecture from ORCA Computing.
  • By uniting efforts, the SupremeQ consortium aims to drive breakthrough innovation in photonic quantum computing, paving the way for quantum advantage.
  • These advancements are necessary for the commercialization of quantum computers to reach advantage over classical computing systems signifying a significant leap toward achieving universal fault-tolerant quantum computing.

National Bank Investments Inc. and Evovest Inc. Launch the Evovest Global Equity ETF

Retrieved on: 
Jeudi, mars 28, 2024
Toronto Stock Exchange, TSX, NBI, ETF

MONTREAL, March 28, 2024 /CNW/ - National Bank Investments Inc. ("NBI" or the "Investment Fund Manager") and Evovest Inc. ("Evovest" or the "Portfolio Manager") (together, the "Promoters") announced today the launch of the Evovest Global Equity ETF (the "ETF").

Key Points: 
  • MONTREAL, March 28, 2024 /CNW/ - National Bank Investments Inc. ("NBI" or the "Investment Fund Manager") and Evovest Inc. ("Evovest" or the "Portfolio Manager") (together, the "Promoters") announced today the launch of the Evovest Global Equity ETF (the "ETF").
  • The ETF has closed the initial offering of units, and those units will start trading on the Toronto Stock Exchange ("TSX") today.
  • "We are proud to announce the launch of the Evovest Global Equity ETF with National Bank Investments, a significant milestone that reflects our continued evolution and team efforts.
  • NBI will act as Investment Fund Manager of the ETF and Evovest will act as Portfolio Manager of the ETF.

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Mercredi, mars 6, 2024
Senior, Research, Fulvestrant, Sale, University, NBI, Tax, MSAT, Plasma, CD28, BTC, NASDAQ Biotechnology Index, Pain, Rat, BLA, Standard of care, Antibody, HER2, MD Anderson Cancer Center, Abstract (summary), GAAP, Therapy, Carcinoma, Abstract, Depreciation, Partnership, Camptothecin, Manuscript, Conference, Partner, IND, NMPA, Jazz Pharmaceuticals, PFS, BeiGene, FDA, Spacecraft, Pembrolizumab, CDX, ADC, OS, Society, Patient, Pharmaceutical industry

Financial Results for the Year Ended December 31, 2023

Key Points: 
  • Financial Results for the Year Ended December 31, 2023
    Revenue was $76.0 million in 2023 compared to $412.5 million in 2022.
  • Higher interest income in 2023 was due to income earned on higher cash resources and at higher rates of return in 2023.
  • “We are happy to report a continued reduction of our operating cash burn and operating losses during 2023 compared to 2022,” said Chris Astle, Ph.D., Senior Vice President and Chief Financial Officer of Zymeworks.
  • Reconciliations between historical GAAP and non-GAAP information are contained at the end of this press release following the accompanying financial data.

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Jeudi, février 29, 2024
Acquisition, Research, Reiterate, Neoplasm, FDA, Cancer, Adium, Disassembler, International Society, NASDAQ Biotechnology Index, Interim, GM-CSF, Self-assembly, NBI, Therapy, Interest, Patient, HITS, Clinical trial, Congress, IND, Human, Cryptocurrency

On October 18, 2023, Y-mAbs announced that its Board of Directors appointed radiopharmaceutical industry veteran Mr. Rossi as President and Chief Executive Officer, effective November 6, 2023.

Key Points: 
  • On October 18, 2023, Y-mAbs announced that its Board of Directors appointed radiopharmaceutical industry veteran Mr. Rossi as President and Chief Executive Officer, effective November 6, 2023.
  • The DANYELZA net product revenues of $23.4 million in the fourth quarter of 2023, represented a favorable 17% increase compared to the third quarter of 2023, primarily driven by increased U.S. sales.
  • The Company did not have license revenues in the quarter ended December 31, 2023 and had license revenues of $0.5 million for the year ended December 31, 2023.
  • The net income for the quarter ended December 31, 2022, was after $15.0 million of license revenue recognized in the fourth quarter of 2022.